Cedilla Therapeutics Competitors and Similar CompaniesClear all
Cedilla Therapeutics's competitors and similar companies include AustinPx, Clovis Oncology, Vivoryon Therapeutics and Pharmacyclics.
 AustinPx AustinPx (formerly Dispersol Technologies) is a company that focuses on formulation and processing technologies for solubility and bioavailability enhancement of poorly water-soluble drug molecules. |  Clovis Oncology Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents. |  Vivoryon Therapeutics Vivoryon Therapeutics (previously known as Probiodrug) is a precision intervention company specializing in discovering and developing therapies for patients suffering from age-related diseases. |  Pharmacyclics Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. | ||
Founding Date | Founding Date 2018 | Founding Date 2007 | Founding Date 2009 | Founding Date 1997 | Founding Date 1991 |
Type | Type Private | Type Private | Type Public | Type Public | Type Subsidiary |
Tags | |||||
Locations | Locations Cambridge, US HQ | Locations Georgetown, US HQ | Locations Halle (Saale), DE HQ München, DE | Locations Sunnyvale, US HQ | |
Employees | Employees 6 | Employees 412% decrease | Employees 4843% increase | Employees 14 | Employees 6551% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 10.6 m | Valuation ($) 69.8 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $148.8m (FY, 2021) | Revenue (est.) N/A | Revenue (est.) $729.7m (FY, 2014) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $40.4m (FY, 2014) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit €265k (FY, 2025) | Gross profit $689.3m (FY, 2014) |
Net income | Net income N/A | Net income N/A | Net income ($264.5m) (FY, 2021) | Net income (€8.9m) (FY, 2025) | Net income $86.1m (FY, 2014) |
Funding | |||||
Latest funding round | Latest funding round $ 25m (over 4 years ago) | Latest funding round $ 27m (about 8 years ago) | Latest funding round N/A | Latest funding round N/A | Latest funding round N/A |
Total funding raised | Total funding raised $ 81.2m | Total funding raised $ 52.7m | Total funding raised $ 357m | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
AustinPx
HQ
Georgetown, US
Employees
41↓ 2% decrease
AustinPx (formerly Dispersol Technologies) is a company that focuses on formulation and processing technologies for solubility and bioavailability enhancement of poorly water-soluble drug molecules.
View companyClovis Oncology
HQ
Boulder, US
Employees
484↑ 3% increase
Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents.
View companyVivoryon Therapeutics
HQ
Halle (Saale), DE
Employees
14
Vivoryon Therapeutics (previously known as Probiodrug) is a precision intervention company specializing in discovering and developing therapies for patients suffering from age-related diseases.
View companyPharmacyclics
HQ
Sunnyvale, US
Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases.
View company